747,410 Shares in TELA Bio, Inc. $TELA Purchased by Velan Capital Investment Management LP

Key Points

• Velan Capital Investment Management LP has acquired 747,410 shares of TELA Bio, Inc., valued at approximately $912,000, making it the firm's 22nd largest position.
• A significant 94.35% of TELA Bio's stock is owned by hedge funds and institutional investors, indicating strong institutional interest.
• Despite reporting a revenue of $20.20 million, TELA Bio missed earnings expectations with a reported EPS of ($0.22), falling short of the consensus estimate.

Velan Capital Investment Management LP purchased a new stake in TELA Bio, Inc. (NASDAQ:TELA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 747,410 shares of the company's stock, valued at approximately $912,000. TELA Bio makes up 0.9% of Velan Capital Investment Management LP's investment portfolio, making the stock its 22nd largest holding. Velan Capital Investment Management LP owned about 1.89% of TELA Bio as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. DAFNA Capital Management LLC purchased a new stake in TELA Bio during the 4th quarter worth approximately $4,352,000. Stonepine Capital Management LLC increased its stake in TELA Bio by 112.0% during the 4th quarter. Stonepine Capital Management LLC now owns 2,353,099 shares of the company's stock worth $7,106,000 after buying an additional 1,243,099 shares in the last quarter. Mink Brook Asset Management LLC purchased a new stake in TELA Bio during the 4th quarter worth approximately $1,078,000. Geode Capital Management LLC increased its stake in TELA Bio by 78.4% during the 4th quarter. Geode Capital Management LLC now owns 311,405 shares of the company's stock worth $941,000 after buying an additional 136,890 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in TELA Bio by 39,329.5% during the 4th quarter. JPMorgan Chase & Co. now owns 133,666 shares of the company's stock worth $404,000 after buying an additional 133,327 shares in the last quarter. Hedge funds and other institutional investors own 94.35% of the company's stock.

TELA Bio Trading Down 6.8%

NASDAQ TELA traded down $0.12 on Wednesday, reaching $1.62. The stock had a trading volume of 99,568 shares, compared to its average volume of 171,682. The firm has a market capitalization of $64.22 million, a price-to-earnings ratio of -1.45 and a beta of 0.84. The company has a quick ratio of 2.59, a current ratio of 3.19 and a debt-to-equity ratio of 4.14. TELA Bio, Inc. has a 12-month low of $0.86 and a 12-month high of $3.26. The stock has a fifty day moving average price of $1.86 and a two-hundred day moving average price of $1.67.

TELA Bio (NASDAQ:TELA - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.04). The company had revenue of $20.20 million for the quarter, compared to analysts' expectations of $20.67 million. TELA Bio had a negative return on equity of 329.48% and a negative net margin of 54.12%. TELA Bio has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that TELA Bio, Inc. will post -1.37 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Wall Street Zen lowered TELA Bio from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, TELA Bio presently has a consensus rating of "Moderate Buy" and a consensus price target of $4.50.

About TELA Bio

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.